Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1488-1497

  Reyes, D ^a,b,c   Salazar, L ^a,c   Espinoza, E ^c   Pereda, C ^a,c   Castellon E ^a   Valdevenito, R ^b   Huidobro, C ^b   Ines Becker M ^d   Lladser, A ^e   Lopez M N ^a,b,c   Salazar Onfray, F ^a,c  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d Fundacion Ciencia y Tecnologia para el Desarrollo   (Chile)

^e Fundacion Ciencia para la Vida   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CD8 ANTIGEN; CONCHOLEPAS CONCHOLEPAS HEMOCYANIN; DENDRITIC CELL VACCINE; FLUTAMIDE; GONADORELIN AGONIST; HEMOCYANIN; KETOCONAZOLE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TRIMEL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CASTRATION RESISTANT PROSTATE CANCER; CELL LYSATE; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; EXTERNAL BEAM RADIOTHERAPY; FLOW CYTOMETRY; GASTROPOD; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LYMPH NODE METASTASIS; MALE; MEMORY T LYMPHOCYTE; ORCHIECTOMY; PATIENT COMPLIANCE; PELVIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE CANCER CELL LYSATE; QUALITY OF LIFE; RADICAL RETROPUBIC PROSTATECTOMY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84884592216     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.494     Document Type: Article

References (42)

1. Aguilera R, Saffie C, Tittarelli A, González FE, Ramirez M, Reyes D, Pereda C, Hevia D, Garcia T, Salazar L, Ferreira A, Hermoso M, Mendoza-Naranjo A, Ferrada C, Garrido P, López MN, Salazar-Onfray F (2011) Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 17: 2474-2483.
2. Arancibia S, Del Campo M, Nova E, Salazar F, Becker MI (2012) Enhanced structural stability of Concholepas hemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects. Eur J Immunol 42: 688-699.
3. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK (2003) Dendritic cells: Controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 987: 180-187.
4. Bracci L, Schiavoni G, Sistigu A, Belardelli F (2013) Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ; e-pub ahead of print 21 June 2013; doi:10.1038/cdd.2013.67.
5. Chiang CL, Kandalaft LE, Coukos G (2011) Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 30: 150-182.
6. De Ioannes P, Moltedo B, Oliva HH, Pacheco R, De Ioannes AE, Becker MI (2004) Hemocyanin of the molluscan Concholepas concholepas exhibits an unusual heterodecameric array of subunits. J Biol Chem 279: 26134-26142.
7. Del Campo M, Arancibia S, Nova E, Salazar F, Gonzalez A, Moltedo B, De Ioannes P, Ferreira J, Manubens A, Becker MI (2011) [Hemocyanins as immunostimulants]. Rev Med Chil 139: 236-246.
8. deVries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ (2005) Immunomonitoringtumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23: 5779-5787.
9. Durán-Aniotz C, Segal G, Salazar L, Pereda C, Falcón C, Tempio F, Aguilera R, González R, Pérez C, Tittarelli A, Catalán D, Nervi B, Larrondo M, Salazar-Onfray F, López MN (2013) The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer Immunol Immunother 62(4): 761-772.
10. Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F (2005) Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 142: 555-568.
11. Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP (2006) Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. Prostate 66: 811-821.
12. Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, Livingston PO (2005) Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity. Vaccine 23(39): 4727-4733.
13. Hart DN (1997) Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90: 3245-3287.
14. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723.
15. Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J Urol 168: 9-12.
16. Idakieva K, Nikolov P, Chakarska I, Genov N, Shnyrov VL (2008) Spectroscopic properties and conformational stability of Concholepas concholepashemocyanin. J Fluoresc 18(3): 715-725.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics (2009) CA Cancer J Clin 59: 225-249.
18. Joffre O, Nolte MA, Spörri R, Reis e Sousa C (2009) Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 227: 234-247.
19. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
20. Klebanoff CA, Gattinoni L, Restifo NP (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224.
21. Kobayashi K, Kaneda K, Kasama T (2001) Immunopathogenesis of delayedtype hypersensitivity. Microsc Res Tech 53: 241-245.
22. Liu Q, Wang Y, Wang H, Liu Y, Liu T, Kunda PE (2013) Tandem therapy for retinoblastoma: Immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol 139(8): 1357-1372.
23. López M, Aguilera R, Pérez C, Mendoza-Naranjo A, Pereda C, Ramirez M, Ferrada C, Aguillón JC, Salazar-Onfray F (2006) The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. Immunobiology 211: 127-136.
24. López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, Escobar A, Ginesta A, Reyes D, González R, Mendoza-Naranjo A, Larrondo M, Compán A, Ferrada C, Salazar-Onfray F (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27: 945-952.
25. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Droin N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L, Kroemer G (2013) Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigenpresenting cells. Immunity 38(4): 729-741.
26. Moltedo B, Faunes F, Haussmann D, De Ioannes P, De Ioannes AE, Puente J, Becker MI (2006) Immunotherapeutic effect of Concholepashemocyanin in the murine bladder cancer model: Evidence for conserved antitumor properties among hemocyanins. J Urol 176: 2690-2695.
27. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-583.
28. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005) Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 93: 749-756.
29. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27: 5944-5951.
30. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cells: A phase I/II study. BJU Int 94: 412-418.
31. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
32. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665-1671.
33. Semeniuk RC, Venner PM, North S (2006) Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 68: 565-569.
34. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
35. Shoemaker LK, Estfan B, Induru R, Walsh TD (2011) Symptom management: An important part of cancer care. Cleve Clin J Med 78: 25-34.
36. Sullivan PW, Mulani PM, Fishman M, Sleep D (2007) Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res 16: 571-575.
37. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
38. Tittarelli A, González FE, Pereda C, Mora G, Muñoz L, Saffie C, Garcia T, Diaz D, Falcón C, Hermoso M, López MN, Salazar-Onfray F (2012) Tolllike receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother 61: 2067-2077.
39. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125-129.
40. Watcha MF, White PF (1992) Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 77: 162-184.
41. Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD (2013) Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 13: 7.
42. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369(2): 122-133.